Related Experiment Video
Updated: Aug 15, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
The effectiveness of mupirocin preventing Staphylococcus aureus in catheter-related infections in peritoneal dialysis
E Thodis1, P Passadakis, S Panagoutsos
1Department of Nephrology, Medical School, Democritus University of Thrace, Greece.
Abstract:
The objective of this study was to evaluate the effectiveness of mupirocin on Staphylococcus aureus with regard to peritoneal dialysis (PD)-catheter exit-site infections (ESI), tunnel infections (TI), and peritonitis episodes (PE). The study was performed on 42 continuous ambulatory peritoneal dialysis (CAPD) patients (group I) treated from April 1998 to July 1999. These patients were instructed to apply mupirocin daily at the catheter exit site as part of their exit-site care. The control was the same group's historical infection data. Results were also recorded for a second group of 16 patients (group II) with newly implanted PD catheters were also instructed to apply mupirocin at the exit site daily. During the control period (before daily mupirocin application), group I recorded 16 episodes of ESI (0.30 episodes per patient-year), 6 episodes of TI (0.11 episodes per patient-year), 15 episodes of PE (0.28 episodes per patient-year), and one case of catheter removal (0.019 episodes per patient-year) owing to S. aureus exit-site infection coexisting with peritonitis. The rate of S. aureus exit-site infection during this period was 0.11 episodes per patient-year; of S. aureus tunnel infection, 0.057 episodes per patient-year; and of S. aureus peritonitis, 0.076 episodes per patient-year. During the mupirocin period, infections and peritonitis owing to S. aureus dramatically decreased (p < 0.01 and p < 0.001 respectively). The rate of S. aureus exit-site infection was 0.02 episodes per patient-year, with no S. aureus tunnel infections, and no catheter removals owing to S. aureus peritonitis. Similarly, in group II, no episodes were recorded of any ESI, TI, or PE owing to S. aureus, although 4 episodes of ESI (0.37 episodes per patient-year, 2 with other gram-positive bacteria, and 2 with gram-negative bacteria) and 8 PEs (0.75 episodes per patient-year) were seen. We conclude that mupirocin application provides excellent prophylaxis for catheter-related infections owing to S. aureus, and that reduction of these infections may improve the long-term survival of patients on CAPD.
Insights
Topical mupirocin effectively prevents Staphylococcus aureus infections in peritoneal dialysis (PD) patients. Daily application significantly reduced exit-site infections, tunnel infections, and peritonitis, improving long-term PD patient outcomes.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Catheter-related infections, particularly those caused by Staphylococcus aureus, are a significant complication in patients undergoing peritoneal dialysis (PD).
- These infections, including exit-site infections (ESI), tunnel infections (TI), and peritonitis (PE), can lead to treatment interruption and adverse patient outcomes.
- Preventive strategies are crucial for maintaining the long-term success of PD therapy.
Purpose of the Study:
- To evaluate the efficacy of topical mupirocin in preventing Staphylococcus aureus-related PD-catheter exit-site infections, tunnel infections, and peritonitis episodes.
- To assess the impact of daily mupirocin application on infection rates in continuous ambulatory peritoneal dialysis (CAPD) patients.
Main Methods:
- A study was conducted on two groups of CAPD patients: Group I (42 patients) used historical data as a control before daily mupirocin application and then applied mupirocin daily. Group II (16 patients) with newly implanted catheters also applied mupirocin daily.
- Infection episodes (ESI, TI, PE) and catheter removals due to S. aureus were tracked and compared between the pre-mupirocin (control) and mupirocin application periods for Group I, and prospectively for Group II.
Main Results:
- In Group I, daily mupirocin application significantly decreased S. aureus ESI (from 0.11 to 0.02 episodes/patient-year), TI (from 0.057 to 0), and PE (from 0.076 to 0) (p < 0.01 and p < 0.001).
- No catheter removals due to S. aureus infections were observed during the mupirocin period in Group I.
- Group II experienced no S. aureus-related ESI, TI, or PE, although non-S. aureus infections occurred.
Conclusions:
- Topical mupirocin demonstrates excellent prophylactic efficacy against Staphylococcus aureus-related catheter infections in PD patients.
- The reduction in S. aureus infections through mupirocin use may contribute to improved long-term survival for patients on CAPD.
- Mupirocin is a valuable tool in managing and preventing PD-related infections, particularly those caused by S. aureus.
Related Concept Videos
Parentral Nutrition: Centeral and Peripheral Parental Nutrition
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Urine Studies II: Urine Culture and Sensitivity Test
Staphylococcal Skin Infections
Clinical Significance of Antibiotic Resistance

